Cholesteryl ester transfer protein antagonism by drugs--a poor choice.
Sirtori
Cesare R
CR
Department of Pharmacological Sciences, University of Milano, Milano, Italy. cesare.sirtori@unimi.it
Mombelli
Giuliana
G
D000818:Animals; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D000069059:Atorvastatin; D053480:Cholesterol Ester Transfer Proteins / Q000819:agonists / Q000037:antagonists & inhibitors* / Q000235:genetics; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D020022:Genetic Predisposition to Disease; D006538:Heptanoic Acids / Q000009:adverse effects; D006801:Humans; D011110:Polymorphism, Genetic; D011758:Pyrroles / Q000009:adverse effects; D011804:Quinolines / Q000009:adverse effects; D012306:Risk
D000924:Anticholesteremic Agents; D053480:Cholesterol Ester Transfer Proteins; D006538:Heptanoic Acids; D011758:Pyrroles; D011804:Quinolines; C483909:torcetrapib; D000069059:Atorvastatin